Cardiovascular complications in atypical haemolytic uraemic syndrome

被引:53
|
作者
Noris, Marina [1 ]
Remuzzi, Giuseppe [2 ]
机构
[1] IRCCS, Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo e Cele Dacco, I-24020 Bergamo, Italy
[2] Azienda Osped Papa Giovanni XXIII, Unit Nephrol & Dialysis, I-24100 Bergamo, Italy
关键词
FACTOR-H-AUTOANTIBODIES; THROMBOTIC THROMBOCYTOPENIC PURPURA; MEMBRANE COFACTOR PROTEIN; MYOCARDIAL-INFARCTION; PERIPHERAL GANGRENE; CLINICAL CHARACTERISTICS; COMPLEMENT; MUTATIONS; IMPACT; MICROANGIOPATHIES;
D O I
10.1038/nrneph.2013.280
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Haemolytic uraemic syndrome (HUS) is characterized by nonimmune haemolytic anaemia, thrombocytopenia and renal impairment-most incidents in childhood are caused by shiga toxin-producing bacteria. Atypical HUS (aHUS) accounts for 10% of cases and has a poor prognosis. About 60% of patients with aHUS have dysregulation of the alternative complement pathway (complement-mediated aHUS). The kidney is the main target organ, but other organs might also be affected. Cardiac complications occur in 3-10% of patients with complement-mediated aHUS, as a consequence of microangiopathic injury in the coronary microvasculature, and can cause sudden death. Emerging evidence also suggests that either thrombosis or stenosis of the medium and large arteries might complicate disease course, and such disorders occur even after renal function is lost. In this Perspectives article we discuss the impact of cardiovascular involvement in complement-mediated aHUS, the role of acute and chronic complement hyperactivation in such events and the implications for treatment.
引用
收藏
页码:174 / 180
页数:7
相关论文
共 50 条
  • [42] Eculizumab: A guide to its use in atypical haemolytic uraemic syndrome
    Keating G.M.
    Drugs & Therapy Perspectives, 2014, 30 (5) : 166 - 172
  • [43] The Spanish atypical haemolytic uraemic syndrome registry: A genetic update
    de Jorge, Elena Goicoechea
    Barricarte, Ruben Martinez
    Tortajada, Agustin
    Montes, Tamara
    Pinto, Sheila
    Garrido, Cyn-Thia Aberrategui
    Lopez-Trascasa, Margarita
    Sanchez-Corral, Pilar
    de Cordoba, Santiago Rodriguez
    MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3923 - 3923
  • [44] Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
    Verhave, Jacobien C.
    Wetzels, Jack F. M.
    van de Kar, Nicole C. A. J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 131 - 141
  • [45] Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
    Servais, Aude
    Devillard, Nadege
    Fremeaux-Bacchi, Veronique
    Hummel, Aurelie
    Salomon, Laurent
    Contin-Bordes, Cecile
    Gomer, Helene
    Legendre, Christophe
    Delmas, Yahsou
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (12) : 2122 - 2130
  • [46] Anything but typical: recognising postpartum atypical haemolytic uraemic syndrome
    Eslick, R.
    Motum, P.
    Watson, A.
    Hsu, D.
    THROMBOSIS RESEARCH, 2017, 151 : S114 - S114
  • [47] Atypical haemolytic uraemic syndrome and its treatment: A case report
    Khan, Azhar Ali
    Ahraf, Muhammad Usman
    Javaid, Usman
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (05) : 1496 - 1498
  • [48] Haemolytic Uraemic Syndrome
    Kavanagh, David
    Goodship, Tim
    NEPHRON CLINICAL PRACTICE, 2011, 118 (01): : C37 - C42
  • [49] Haemolytic uraemic syndrome
    Robson Wm.L.M.
    Paediatric Drugs, 2000, 2 (4): : 243 - 252
  • [50] Haemolytic uraemic syndrome
    Michael, Mini
    Bagga, Arvind
    Sartain, Sarah E.
    Smith, Richard J. H.
    LANCET, 2022, 400 (10364): : 1722 - 1740